What theyre saying: While the new generation of incretin therapies have been revolutionary for patients living with obesity, bimagrumab addresses a critical unmet need as a therapeutic that targets fat loss while building muscle mass. Versanis CEO Mark Pruzanski The solo act The drug: Altimmunes pemvidutide is a combination GLP-1 agonist and glucagon agonist
Some prescribers add a baseline cortisol because ipamorelin's selectivity advantage over older secretagogues is partly its minimal effect on cortisol, and confirming that advantage requires a baseline
So once he heard about Raufmans discovery, he shipped a live gila monster to Canada, then studied its venom and the genes behind the protein that works like GLP-1
Lilly reported two average weight-loss figures for each dose, based on two ways of analysing the same trial (known as estimands)
Zhang D, Zhang X, Zeng M, et al
I think it needs to be over 30 if they don't have those comorbidities, that's for the obesity
